Novavax sees weak Covid vaccine sales
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback